Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Boosting killer cells might improve breast-cancer drug

17.07.2006
Preliminary research suggests that a drug that targets a particular type of breast cancer might be more effective if patients are also given a substance made by the body that stimulates certain immune cells.

The laboratory and animal study suggests that the substance interleukin 21 (IL-21) might improve the effectiveness of the drug Herceptin. The findings suggest that this happens because the IL-21 boosts the cancer-killing activity of immune cells called natural killer (NK) cells, which attack the tumor.

The findings by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are published in the July 1 issue of The Journal of Immunology. The researchers hope to begin a clinical trial to test the strategy in humans soon.

Herceptin is used to treat HER2-positive breast cancer -- about 20 percent of all breast-cancer cases. HER2 breast cancers have a protein called HER2 on the surface of the tumor cells. Herceptin attaches to the HER2 protein and coats the cells.

The findings indicate that IL-21 stimulates NK cells to attack and destroy the Herceptin-coated cells.

“Only 25 to 35 percent of patients with this form of breast cancer respond to Herceptin,” says principal investigator William E. Carson, III, associate professor of surgery and associate director for clinical research at the OSU Comprehensive Cancer Center .

“Our results suggest that giving IL-21 along with the Herceptin might increase the patient's immune response to the tumor and perhaps boost the drug's effectiveness.”

Many researchers believe that Herceptin works because it stops tumor cells from growing and causes them to self-destruct through a natural process called programmed cell death, explains first author Julie M. Roda, a graduate research associate in Carson 's laboratory.

But, Roda says, “our findings provide new evidence that Herceptin works at least in part by stimulating NK cells activity, and that IL-21 enhances that action.”

Carson, Roda and their collaborators chose to study IL-21 because the substance is known to activate NK cells and causes them to release substances that attract other immune cells to a tumor site.

This study's findings came from several experiments. First, the scientists exposed NK cells in Petri dishes to both Herceptin and IL-21. This caused the cells to release three to 10 times more of a substance called interferon gamma than would cells exposed to either agent alone.

Interferon gamma is an immune-system signaling agent that causes the NK cells to become more active. It also increases the activity of other immune cells and forces tumor cells to self-destruct.

The researchers then repeated this experiment in mice. They found that animals given both IL-21 and Herceptin-coated tumor cells had nearly three times more interferon gamma in their blood than did animals injected with either of those items alone.

Still another experiment used mice with HER2-positive tumors. When the animals were treated with both the mouse version of Herceptin and IL-21, the tumors shrunk by nearly half compared to those in mice receiving either agent alone.

Last, to test whether the interferon gamma was important for causing the tumors to shrink, the researchers repeated this experiment using mice that cannot make the substance.

The researchers were surprised to find that when interferon gamma was missing, the mouse drug and IL-21 combination had no effect on the tumors.

“We thought if we took out interferon gamma, the NK cells would still be able to kill the tumor cells,” Roda says.

But that didn't happen

“This is very interesting because it suggests that interferon gamma production might be critical to the response to Herceptin, and I believe that we are the first to show this.”

Overall, says Carson , “Our results suggest that IL-21 might enhance the effectiveness of Herceptin, and perhaps similar anticancer drugs.”

Funding from the National Cancer Institute supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://www.osumc.edu

More articles from Life Sciences:

nachricht Tag it EASI – a new method for accurate protein analysis
20.06.2018 | Max-Planck-Institut für Biochemie

nachricht How to track and trace a protein: Nanosensors monitor intracellular deliveries
19.06.2018 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Creating a new composite fuel for new-generation fast reactors

20.06.2018 | Materials Sciences

Game-changing finding pushes 3D-printing to the molecular limit

20.06.2018 | Materials Sciences

Could this material enable autonomous vehicles to come to market sooner?

20.06.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>